OCTAGON CAPITAL ADVISORS LP
Q1 2024 Form 13-F
NEW YORK, NEW YORK
CIK 0001839435
· CRD 306424
· SEC-registered investment adviser
$834.4M Reported Value Total
OCTAGON CAPITAL ADVISORS LP reports 6 total accounts under management (AUM). There are 6 discretionary accounts valued at $951,771,000, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
4 funds
· $1.2B gross asset value
Hedge Fund: $975.2M · Private Equity Fund: $200.1M
Source: Form ADV filed 2026-03-20
Reported value
$834.4M
Quarter over quarter
+5.4%
Holdings
56
Top-10 concentration
55.4%
Key People
Form ADV owners & control persons
Ting (nmn) Jia
FOUNDER, PORTFOLIO MANAGER, AND LIMITED PARTNER
Justin M Hirsch
CHIEF COMPLIANCE OFFICER AND CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2024 13F record
Q1 2024 13F filing summary
| Period of report | March 31, 2024 |
|---|---|
| Filed | May 15, 2024 |
| Form | 13F-HR |
| Reported value | $834.4M |
| Positions | 56 |
| Change in reported value | +33.5% |
| New positions | 33 |
| Exited positions | 10 |
| Position turnover | 65.2% |
| Top-10 concentration | 55.4% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
26 | $1.1B |
|
Q1 2026 13F
Filed May 15, 2026
|
29 | $903.6M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
26 | $823.7M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
26 | $659.8M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
30 | $455.6M |
|
Q1 2025 13F
Filed May 15, 2025
|
34 | $516.8M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
31 | $607.7M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
41 | $642.9M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
44 | $636.3M |
|
Q1 2024 13F
Filed May 15, 2024
|
56 | $834.4M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
33 | $625.0M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
35 | $650.9M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
40 | $718.7M |
|
Q1 2023 13F
Filed May 15, 2023
|
35 | $695.0M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
32 | $642.2M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
35 | $579.4M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
20 | $374.7M |
|
Q1 2022 13F
Filed May 16, 2022
|
24 | $462.6M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
28 | $513.9M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
30 | $406.1M |
3 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q1 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | APLS APELLIS PHARMACEUTICALS INC | $165.0M | 19.77% |
| 2 | ALPN ALPINE IMMUNE SCIENCES INC | $49.2M | 5.9% |
| 3 | DNTH DIANTHUS THERAPEUTICS INC | $41.4M | 4.96% |
| 4 | VRNA VERONA PHARMA PLC | $38.1M | 4.57% |
| 5 | DYN DYNE THERAPEUTICS INC | $35.3M | 4.23% |
| 6 | AVBP ARRIVENT BIOPHARMA INC | $34.7M | 4.16% |
| 7 | INSM INSMED INC | $30.9M | 3.71% |
| 8 | CNTA CENTESSA PHARMACEUTICALS PLC | $23.3M | 2.79% |
| 9 | EYPT EYEPOINT PHARMACEUTICALS INC | $22.6M | 2.71% |
| 10 | OCUL OCULAR THERAPEUTIX INC | $22.1M | 2.64% |
| 11 | GPCR STRUCTURE THERAPEUTICS INC | $21.7M | 2.6% |
| 12 | BBIO BRIDGEBIO PHARMA INC | $21.3M | 2.56% |
| 13 | MNMD MIND MEDICINE MINDMED INC | $20.2M | 2.43% |
| 14 | CATX PERSPECTIVE THERAPEUTICS INC | $17.5M | 2.1% |
| 15 | CRBP CORBUS PHARMACEUTICALS HLDGS | $15.9M | 1.9% |
| 16 | PRAX PRAXIS PRECISION MEDICINES I | $15.9M | 1.9% |
| 17 | TNYA TENAYA THERAPEUTICS INC | $14.9M | 1.79% |
| 18 | JSPR JASPER THERAPEUTICS INC | $14.7M | 1.76% |
| 19 | ANNX ANNEXON INC | $14.7M | 1.76% |
| 20 | CYTK CYTOKINETICS INC | $13.6M | 1.63% |
Values as reported on the Q1 2024 Form 13F. Every position is in the holdings table below.